| Acalabrutinib and Duvelisib for the Treatment of Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (NCT04836832) | Narendranath Epperla | 2022-07-01 |
| Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma (NCT04587687) | University of California, Davis | 2020-12-04 |
| CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma (NCT04578600) | Joseph Tuscano | 2020-10-23 |
| An Early Phase Study of Venetoclax, Lenalidomide, and Rituximab/Hyaluronidase in Slow-Growing Lymphomas That Have Come Back After Treatment or Have Not Responded to Treatment (NCT04447716) | Thomas Jefferson University | 2020-10-16 |
| Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies (NCT04205409) | University of Washington | 2020-06-05 |
| Copanlisib and Combination Chemotherapy for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Relapsed Grade 3b Follicular Lymphoma (NCT04156828) | University of Washington | 2020-03-31 |
| CAR.CD19-CD28-zeta-2A-iCasp9-IL15-Transduced Cord Blood NK Cells, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Participants With B-cell Lymphoma (NCT03579927) | M.D. Anderson Cancer Center | 2019-10-03 |
| Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas (NCT03598998) | City of Hope Medical Center | 2019-02-04 |
| Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma (NCT03479268) | City of Hope Medical Center | 2018-04-27 |
| Pembrolizumab With Rituximab or Obinutuzumab in Treating Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B Cell Lymphoma (NCT03401853) | University of Washington | 2018-03-23 |
| Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma (NCT03269669) | National Cancer Institute (NCI) | 2018-01-23 |
| A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas (NCT03277729) | Fred Hutchinson Cancer Center | 2017-12-05 |
| Umbilical Cord Blood NK Cells, Rituximab, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma (NCT03019640) | M.D. Anderson Cancer Center | 2017-10-10 |
| Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin Lymphoma (NCT03035331) | Mayo Clinic | 2017-08-15 |
| Pembrolizumab and Vorinostat in Patients With Relapsed or Refractory DLBCL, FCL or HL. (NCT03150329) | City of Hope Medical Center | 2017-07-18 |
| Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lymphoma (NCT03147885) | Barbara Ann Karmanos Cancer Institute | 2017-06-20 |
| Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (NCT02992522) | Beth Christian | 2017-02-21 |
| Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma (NCT02950220) | Kami Maddocks | 2017-01-12 |
| TLR9 Agonist SD-101, Ibrutinib, and Radiation Therapy in Treating Patients With Relapsed or Refractory Grade 1-3A Follicular Lymphoma (NCT02927964) | Robert Lowsky | 2016-11-07 |
| Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant (NCT02869633) | Vanderbilt-Ingram Cancer Center | 2016-11-01 |
| Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant (NCT02797470) | AIDS Malignancy Consortium | 2016-06-23 |
| Anti-CD22 CAR-T Therapy for CD19-refractory or Resistant Lymphoma Patients (NCT02721407) | Xinqiao Hospital of Chongqing | 2016-03-01 |
| Memory-enriched CAR-T Cells Immunotherapy for B Cell Lymphoma (NCT02652910) | Xinqiao Hospital of Chongqing | 2015-12-01 |
| Efficacy of Palliative Low-Dose Involved-Field Radiation Therapy for Recurrent Advanced Follicular Lymphoma (NCT02438501) | Di Deng | 2015-10-01 |
| Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia (NCT02153580) | City of Hope Medical Center | 2014-09-24 |
| Lenalidomide and Obinutuzumab in Treating Patients With Relapsed Indolent Non-Hodgkin Lymphoma (NCT01995669) | M.D. Anderson Cancer Center | 2014-05-27 |
| Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (NCT01955499) | National Cancer Institute (NCI) | 2013-09-24 |
| Lenalidomide and Idelalisib in Treating Patients With Recurrent Follicular Lymphoma (NCT01644799) | Alliance for Clinical Trials in Oncology | 2013-08-02 |
| Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas (NCT01897012) | National Cancer Institute (NCI) | 2013-07-17 |
| Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma (NCT01381692) | National Cancer Institute (NCI) | 2011-07-20 |
| Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies (NCT01028716) | Fred Hutchinson Cancer Center | 2010-05-19 |
| Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer (NCT00723099) | Fred Hutchinson Cancer Center | 2008-06-25 |